real-time news and commentary for investors
Friday, Oct 4
Tekmira Pharmaceuticals rises on TKM-PLK1 data
- Tekmira Pharmaceuticals (TKMR) gives an update on the Phase I/II progress of
TKM-PLK1 in patients with neuroendocrine tumors.
- 40% of patients with either GI-NETs or ACCs "showed clinical benefit."
- Specifically, three out of four ACC patients and one GI-NET patient achieved stable disease, while another GI-NET patient showed a partial response (RECIST). (PR)
- TKMR +5.7% premarket.